SGN Nanopharma

What SGN Nanopharma does

SGN Nanopharma Inc. is a Tampa, Florida-based clinical-stage nano-pharmaceutical company founded in 2010 that develops combination therapeutics using its proprietary Micellar Nanoparticle (MNP) drug delivery platform. The company targets complex chronic diseases with multi-factorial etiologies — specifically dry eye disease, chronic pain (including medically refractory pain), and diabetic neuropathy — where existing mono-therapeutic approaches leave significant unmet need. Its clinical pipeline comprises three products in clinical proof-of-concept stages: MNP-Cyclosporine (SGN-101) for dry eye disease, a fixed-dose combination pain topical nanolotion (SGN-624), and an MNP topical nanolotion for diabetic neuropathy (SGN-516). SGN-101 has demonstrated statistical superiority versus Allergan's Restasis in clinical studies published in BMC Ophthalmology, with better tolerability beginning at four weeks; SGN-516 produced 50-80% improvement from baseline in 15 of 19 patients within one month; and SGN-624 enabled 16 of 25 opioid-using patients to either discontinue opioids or halve their dose after one month of treatment.

The MNP platform is engineered to enhance potency, safety, and bioavailability of combination therapeutics for chronic indications by improving API delivery, shortening action time, and reducing side effects relative to standard-of-care small molecules. SGN has completed a pre-IND meeting with the US FDA and obtained regulatory guidance enabling Phase 3 design for SGN-101. The company has also cultivated a long-running research collaboration with the University of South Florida under Florida I4 HiTech Corridor Grants, generating more than $1 million in matching R&D funding over six-plus years and producing a steady talent pipeline.

SGN operates a licensing- and partnership-driven commercialization model rather than building an internal sales force. In Q2 2023, it signed a ~$6.5 million strategic development partnership with a US-based CDMO that will perform CMC development, supply clinical trial materials, and acquire commercial manufacturing rights to all three pipeline products in exchange for $2.7 million in cash equity over one year. Regional distribution has been out-licensed to Medicom Healthcare (semi-exclusive, preservative-free MNP-Cyclosporine in India) and Wellesta Healthcare Singapore (India, SEA, MENA, plus exclusive distribution of SGN's hair growth product range in India). The company is founder-led by Dr. Navdeep Jaikaria (Chairman & CEO) with operating leadership from Vineet Singhal (COO, ex-Shire/Baxalta/Takeda and Novartis) and Dr. Pranav Patel (VP R&D, 25+ years of FDA-approved product development experience).

Name

SGN Nanopharma

Legal name

SGN Nanopharma Inc.

Website

https://sgn.bio

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

SGN Nanopharma Inc. is a Tampa-based clinical-stage nano-pharmaceutical company developing combination therapeutics via its proprietary Micellar Nanoparticle platform for dry eye disease, chronic pain, and diabetic neuropathy, commercializing through licensing and regional distribution partnerships.

Ownership category

akta.pro rank

Product category

Nanopharmaceutical Drug Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Nanotechnology (541713)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Nanopharmaceutical drug delivery
• Micellar nanoparticle platform
• Combination nano-therapeutics
• Ophthalmic nanomedicines
• Topical nanolotion formulations

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Revenue model

1. Pharmaceutical Licensing and Development: The company develops nano-therapeutics through clinical stages and appears to pursue out-licensing partnerships for commercialization, with a CDMO partner acquiring commercial manufacturing rights in exchange for equity and development support.

Go-to-market motion1 record

Core offering

SGN Nanopharma develops clinically differentiated nano-therapeutics using its proprietary Micellar Nanoparticle (MNP) drug delivery platform. The company's pipeline comprises three combination nanomedicines—MNP Cyclosporine (SGN-101) for dry eye disease, a Pain Topical Nanolotion (SGN-624), and an MNP Topical Nanolotion (SGN-516) for diabetic neuropathy—designed to enhance potency, safety, and bioavailability as alternatives to current standard-of-care treatments. SGN pursues out-licensing and CDMO partnerships to bring these products through clinical and commercial stages.

Product overview

SGN Nanopharma is developing a portfolio of combination nano-therapies built on its proprietary Micellar Nanoparticle (MNP) drug delivery platform. The company's clinical pipeline includes three products targeting large unmet medical needs: MNP Cyclosporine (SGN-101) for Dry Eye Disease, a Pain Topical Nanolotion (SGN-624) for pain management, and an MNP Topical Nanolotion (SGN-516) for Diabetic Neuropathy. These nano-formulations aim to enhance the potency, safety, and bioavailability of combination therapeutics for chronic diseases with multi-factorial etiologies, providing alternatives to traditional medicines such as opiates.

Differentiator

Problem solved

Functional benefit

Products and services

• MNP Cyclosporine (SGN-101) A micellar nanoparticle formulation of cyclosporine for Dry Eye Disease (DED). Demonstrated to be statistically superior to Restasis in clinical studies beginning at 4 weeks of treatment, with improved tolerability. Targeted at ophthalmology patients and pharmaceutical licensees seeking differentiated dry eye therapeutics.
• Pain Topical Nanolotion (SGN-624) A transdermal, fixed-dose combination topical nanolotion targeting inflammation and neuropathic components of pain. Demonstrated significant efficacy in patients with medically refractory pain, including opioid-sparing effects (16 of 25 opioid-using patients discontinued or halved dose after one month of treatment). Targeted at chronic pain patients and pharmaceutical licensees.
• MNP Topical Nanolotion for Diabetic Neuropathy (SGN-516) A micellar nanoparticle topical nano-lotion formulation for the treatment of diabetic neuropathy. In clinical studies, 15 of 19 patients showed 50-80% improvement from baseline within one month of treatment. Targeted at diabetic neuropathy patients and pharmaceutical licensees.

Quantifiable outcome

• MNP Cyclosporine was statistically superior to Restasis beginning 4 weeks of treatment and more tolerable in dry eye disease study
• +3 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• US-based CDMO (Contract Development and Manufacturing Organization)coreStrategic or Co-development Partner · 1 April 2023SGN entered a ~$6.5MM Strategic Development Partnership with a US-based CDMO in Q2 2023 for three pipeline products. The CDMO will generate CMC packages for Phase-3 IND filings, supply clinical trial materials, and will acquire commercial manufacturing rights. The CDMO will infuse $2.7MM in cash as equity investment in SGN Nanopharma over one year.
• University of South Florida (USF)coreStrategic or Co-development PartnerSGN Nanopharma has three actively funded research programs from the State of Florida (Florida I4 HiTech Corridor Grants) in collaboration with USF. Over the past six-plus years, more than 65 USF Master's students have conducted thesis research and internships at SGN labs under Dr. Pranav Patel. SGN has hired over two dozen USF graduates. Total matching funding for R&D exceeds $1 million.
• Medicom HealthcareminorChannel Partner/ Reseller/ DistributorMedicom Healthcare is a fast-growing company in the Global Ophthalmic Market providing high-quality eyecare products. They are SGN's semi-exclusive partner for preservative-free MNP Cyclosporine in the Indian market.
• Wellesta Healthcare Singapore Pte. LtdminorChannel Partner/ Reseller/ DistributorWellesta Healthcare Singapore, a subsidiary of Wellesta Holdings Pte Ltd, provides commercial support and market access in India, SEA, and MENA. They are SGN's partner for MNP Cyclosporine in India, SEA, and MENA, and exclusive distribution partner for SGN's hair growth range of products in India.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nanoform Finland: Finnish nanoparticle-enabled drug delivery company using proprietary nanonization technology to enhance bioavailability of small-molecule drugs. Direct peer to SGN's MNP platform in applying nanotechnology to improve drug performance and address formulation challenges of existing APIs.
• Crititech (Hovione): Nanoparticle drug delivery company (acquired by Hovione) specializing in precipitation-based nano-formulations for oncology and other indications. Comparable as a contract-development nanoparticle platform supporting reformulation of existing small molecules.
• Acuitas Therapeutics: Canadian lipid nanoparticle (LNP) delivery technology company partnering with vaccine and therapeutic developers (including Pfizer/BioNTech for COVID-19). Closely comparable as a small-to-mid private nanoparticle drug delivery platform with multiple partner-driven programs.
• NanoCarrier Co., Ltd. Tokyo-listed micellar nanoparticle pharmaceutical company developing polymeric micelle formulations of anti-cancer and other drugs. Direct peer using micellar nanoparticle technology to reformulate existing compounds with improved delivery profiles.

Emerging players

• Kala Bio: Clinical-stage ophthalmology company developing nanoparticle-based therapies for front and back-of-eye diseases. Closely comparable to SGN-101 as a small ophthalmology drug delivery player using proprietary particle technology to address dry eye and related indications.
• Aerie Pharmaceuticals: Ophthalmology-focused company developing small-molecule therapies for glaucoma and dry eye. Comparable as a focused ophthalmology peer pursuing differentiated formulations in adjacent front-of-eye indications.
• Ocular Therapeutix: Clinical and commercial-stage ophthalmology drug delivery company with products in dry eye and other indications. Comparable as an ophthalmology-focused drug delivery peer using proprietary formulation technology and pursuing out-licensing/partnership strategies.

Broad incumbents

• Allergan / AbbVie: Marketer of Restasis (cyclosporine ophthalmic), the standard-of-care dry eye therapy that SGN-101 demonstrated superiority over in a head-to-head study. Broad incumbent in ophthalmology and the key competitive benchmark for SGN-101's value proposition.
• Bausch + Lomb: Large ophthalmology franchise covering dry eye (e.g., Miebo), prescription ophthalmics, and lens care. Broad incumbent competing in the same dry eye market SGN-101 targets, and a plausible strategic acquirer or licensing partner.
• Novartis: Global pharmaceutical major with deep ophthalmology (Xiidra for dry eye) and pain/neurology franchises, and prior employer of SGN COO Vineet Singhal. Plausible out-licensing partner or strategic acquirer for SGN's portfolio given overlap with SGN-101 (Xiidra competitor) and SGN-624/SGN-516 pain indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sgn-nanopharma-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SGN Nanopharma